-

Abstract

Metabolic syndrome is one of the main factors for development of diabetes mellitus and cardiovascular diseases. It was shown that earlystage renal injury was developed in cases with metabolic syndrome. Detection of early-stage renal injury and its treatment seem to be good approach for prevention in cardiovascular and all-cause mortality and morbidity. In the study, it was aimed to compare the methods of CystatinC, Tc99m Mag-3 renal scan and microalbuminuria in detecting early stage of renal injury in patients with metabolic syndrome. A significant difference for serum cystatin-c and urinary microalbuminuria between groups was detected. Mean urinary albumin-creatinine ratio and serum cystatin-C level was significantly higher in patient with metabolic syndrome, compared to individuals in control group (26.4 ± 3.8 mg/g versus 4.9 ± 0.9 mg/g; p = 0.005 and 0.76 ± 0.07 mg/dL versus 0.59 ± 0.05 mg/dL; p = 0.002). Results of Tc99m mag–3 renal scan for both right and lest kidneys were similar (R: 49.4 ± 6.3 % versus 51.7 ± 7.1 %, p = 0.113; L: 50.8 ± 4.8 % versus 48.3 ± 5.9 %, p = 0.202). Mean serum hs-CRP (5.1 ± 0.7 mg/dL versus 1.8 ± 0.3 mg /dL; p < 0.001) and uric acid level (6.7 ± 1.1 mg/dL versus 4.6±1.6 mg/dL; p < 0.001) in patients with metabolic syndrome was detected as significantly higher than among individuals in control group

Keywords

• -

Metabolik Sendrom Hastalarında Erken Dönem Böbrek Hasarının Saptanmasında Mikroalbuminuri, Sistatin-C ve Tc99m Mag–3 Böbrek Sintigrafisi Yöntemlerinin Karşılaştırılması

Abstract

Metabolik sendrom diyabetes mellitus ve kalp-damar hastalıklarının gelişmesinde en önemli faktörlerden birisidir. Metabolik sendrom olgularında erken dönem renal hasarın oluştuğu gösterilmiştir. Erken dönem renal hasarın saptanması ve tedavi başlanması kardiyovaskuler ve tüm nedenlere bağlı mortalite ve morbiditenin önlenmesinde önemli yaklaşım olacaktır. Bu araştırmada metabolik sendrom olgularında erken dönem böbrek hasarının saptanmasında mikroalbüminüri, cystatin-c ve Tc99m mag–3 böbrek sintigrafisi yöntemlerinin karşılaştırılması amaçlanmıştır. Gruplar arasında Sistatin-C ve idrar mikroalbüminüri açısından anlamlı fark izlendi. Metabolik sendrom olgularında idrar mikroalbüminüri-kreatinin oranı (26,4 ± 3,8 mg/g ve 4,9 ± 0,9 mg/g; p = 0,005) ve serum sistatin-C (0,76 ± 0,07 mg/dL ve 0,59 ± 0,05 mg/dL; p = 0,002) ortalaması kontrol grubu olgularına göre yüksek saptandı. Tc99m mag–3 böbrek sintigrafisi hem sağ hem de sol böbrek için her iki grupta benzer saptandı (Sağ: 49,4 ± 6,3 % ve 51,7 ± 7,1 %, p = 0,113; Sol: 50,8 ± 4,8 % ve 48,3 ± 5,9 %, p = 0,202). Metabolik sendrom olgularında serum hs-CRP (5,1 ± 0,7 mg/dL ve 1.8 ± 0,3 mg /dL; p < 0,001) ve ürik asit seviyeleri (6,7 ± 1,1 mg/dL ve 4,6 ± 1,6 mg/dL; p < 0,001) kontrol grubu olgularına göre anlamlı düzeyde yüksek saptandı

Keywords

• Metabolik Sendrom, Cystatin-C, Tc99m Mag–3 Böbrek Sintigrafisi, Nefropati,

References

1. Alegria Ezquerra E, Castellano Vázquez JM, Alegria Barrero A. Obesity, metabolic syndrome and diabetes: cardiovascular implications and therapy. Rev Esp Cardiol 2008; 61(7):752-64.
2. Demir D, Erten Bucaktepe G, Kara IH. The comparing of the sociodemographic features, anthropometric and biochemical parameters of the cases with metabolic syndrome, type 2 diabetes mellitus and healthy controls. Konuralp Tıp Dergisi [Konuralp Medical Journal] 2010; 2(1): 12–19.
3. Yoshida T, Takei T, Shirota S, et al. Risk factors for progression in patients with early-stage chronic kidney disease in the Japanese population. Intern Med. 2008; 47(21): 1859-64.
4. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140(3):167-74.
5. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: A systematic review and meta-analysis. Kidney Int 2008; 73(1):19-33.
6. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16(7):2134-40.
7. Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard Bagnis C. Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med. 2008; 121(5):426–32.
8. Borges RL, Hirota AH, Quinto BM, Ribeiro AB, Zanella MT, Batista MC. Is cystatin C a useful marker in the detection of diabetic kidney disease? Nephron Clin Pract. 2010; 114(2):127-34.

9. Esteves FP, Taylor A, Manatunga A, Folks RD, Krishnan M, Garcia EV. 99mTc-MAG3 renography: normal values for MAG3 clearance and curve parameters, excretory parameters, and residual urine volume. AJR Am J Roentgenol. 2006; 187(6): 610–7.
10. Esteves FP, Halkar RK, Issa MM, Grant S, Taylor A. Comparison of camera-based 99mTc-MAG3 and 24- hour creatinine clearances for evaluation of kidney function. AJR Am J Roentgenol. 2006; 187(3): 316–9.
11. World Health Organization and International Diabetes Federation. Definition, diagnosis and classification of diabetes http://whqlibdoc.who.int/publications/2006/9241594934_eng.pdf (Accessed in January 2011). and its
12. complications. Geneva, Switzerland: WHO, 1999.
13. National Institutes of Health. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): NIH Publication No. 02- 5215. September 2002.
14. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002;106(3):286-8.
15. Bayram F, Gundogan K, Ozturk A, Yazıcı C. Dünya'da ve Türkiye'de Metabolik Sendromun Dağılımı [Prevalence of Metabolic Syndrome in The World and Turkey]. Turkiye Klinikleri J Int Med Sci 2006; 2(3):18-24.
16. Hoehner CM, Greenlund KJ, Rith-Najarian S, Casper ML, McClellan WM. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol. 2002;13(6):1626-34.
17. Utsunomiya K, Takamatsu K, Fukuta I, et al. Association of urinary albumin excretion with insulin resistance in Japanese subjects: impact of gender difference on insulin resistance. Intern Med. 2009;48(18):1621-7.
18. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 47(5):793-800.
19. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29(8):439-93.
20. KhashabMA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep 2008; 10(1):73-80.
21. Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005; 293(15):1868-74.
22. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113(15):1888- 904.
23. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13(12):2888-97.
24. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005;67(5):1739-42.
25. Schelling JR, Sedor JR. The metabolic syndrome as a risk factor for chronic kidney disease: More than a fat chance? J Am Soc Nephrol 2004; 15(11):2773–4.
26. Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007;50(2): 239-47.
27. Lim HS, Patel JV, Lip GY. Metabolic syndrome: a definition in progress. Circulation 2004, 110(4): e35.
28. Warwas M, Piwowar A. Urinary cystatin C as a biomarker of renal tubular injury. Postepy Hig Med Dosw (Online). 2011; 65: 562-8.
29. Uslu S, Kebapçi N, Kara M, Bal C. Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Ther Med. 2012; 4(1):113-20.
30. Hu D, Hannah J, Gray RS, et al. Effects of obesity and body fat distribution on lipids and lipoproteins in nondiabetic American Indians: The Strong Heart Study. Obes Res 2000; 8(6):411-21.
31. Davidson MH. Management of Dyslipidemia in Patients with Complicated Metabolic Syndrome. American Journal of Cardiology 2005; 96(4A):22E-25E.